Recombinant Anti-DR5 x Anti-FAP Bispecific Antibody (scIgG) (SCIGG-152)

Recombinant Anti-DR5 x Anti-FAP Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-DR5 and anti-FAP IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can induce targeted apoptosis by activation of the death receptor. It is designed for the research of Breast cancer; Ovary cancer; Colon cancer; Lung cancer therapy.

Datasheet INQUIRY

Specifications

Targets

DR5 & FAP

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Breast cancer; Ovary cancer; Colon cancer; Lung cancer

Targets

Target 1

DR5

Gene ID

8795

UniProt ID

O14763

Alternative Names

DR5; Death Receptor 5; CD262; KILLER; TRICK2; TRICKB; ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-R2; KILLER/DR5; Tumor necrosis factor receptor superfamily member 10B; TNFRSF10B

Target 2

FAP

Gene ID

2191

UniProt ID

B4DLR2

Alternative Names

FAP; fibroblast activation protein, alpha; FAPA; SIMP; Fibroblast activation protein; DPPIV; prolyl endopeptidase FAP; seprase; FAPalpha; dipeptidyl peptidase FAP; surface-expressed protease; post-proline cleaving enzyme; gelatine degradation protease FAP; F19 cell surface antigen; integral membrane serine protease; serine integral membrane protease; 170 kDa melanoma membrane-bound gelatinase

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-DR5 x Anti-FAP Bispecific Antibody (scIgG) (SCIGG-152). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-DR5 x Anti-FAP Bispecific Antibody (scIgG) (CAT#: SCIGG-152)

Specifications

Targets

Customer Reviews and Q&As